FDA OKs Dupilumab for Moderate-to-Severe Eczema in Teens

Share this post

The "breakthrough" therapy is for adolescents as young as 12 with moderate-to-severe atopic dermatitis poorly controlled with other therapies, or when those therapies are contraindicated.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply